Approval of ellavie for europe(first qr 2011),patent increase of axiron to 2026(first quarter 2011),animal product approval(first quarter 2011) and probably most important royalty stream from the sale of axiron commencing about april this year.If the 60 cent dividend is not able to be franked there will be plenty of franking credits going forward.From what i am hearing there are about 700 eli lilly people in the field who will be selling the product.By the time they start selling the product they would have spent nearly 300 million including up front milestone payments,one would have to say they must be very very confident with the potential of axiron.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.001(6.25%) |
Mkt cap ! $6.116M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.5¢ | $1.574K | 104.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 609316 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 388346 | 2 |
View Market Depth
| Last trade - 11.39am 26/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |